ADMAAnother reminder from the plaintiff bar
ADMA Biologics is getting yet another securities class action deadline notice, this time from Levi & Korsinsky. If you own the stock, you’ve probably noticed the legal popcorn machine has been running overtime.
Why this matters
The underlying story is the same nasty one investors have been chewing on: a short-seller report alleged ADMA’s reported 20% ASCENIV revenue growth was fake and actually masked a 3% decline. That’s the kind of allegation that turns a growth story into a trust issue, which is basically the corporate version of finding out your favorite restaurant has been microwaving the “fresh” bread.
The market doesn’t love this kind of fog
- Class action notices don’t always change the business overnight, but they keep the overhang alive.
- They can add legal costs, management distraction, and a fresh reason for investors to stay skittish.
- And when the core dispute is about reported sales quality, the market tends to stay skeptical until there’s a cleaner answer.
Big picture: this isn’t a new business breakthrough or a shiny product launch. It’s another chapter in a messy credibility saga, and the stock usually pays the price when the storyline is “prove it.”